Cryo-Cell International, Inc. (CCEL)
Full history for every metric is available with a Kvantra account
No price history available.
Key financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 31 | 29 | 30 | 31 | 32 | 32 | 31 | 30 |
| Operating profit | $m | 5 | - | ||||||
| Net profit | $m | 4 | 2 | 3 | -10 | 0 | -2 | -2 | 1 |
| EPS reported | $ | -0.30 | -0.29 | ||||||
| Operating cashflow per share | $ | 0.68 | 0.78 | ||||||
| Capex per share | $ | 0.03 | 0.03 | ||||||
| FCF per share | $ | 0.65 | 0.76 | ||||||
| Free cash flow | $m | 5 | 6 | ||||||
| Net debt | $m | 7 | 5 | ||||||
| Book value equity | $m | -19 | -18 | ||||||
| Book value per share | $ | -2.31 | -2.20 | ||||||
| Number of shares | m | 8.07 | 8.06 | ||||||
| DPS (TTM paid) | $ | 0.40 | 0.00 |
Financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | - | - | ||||||
| P/B LTM | x | -1.73 | -1.81 | ||||||
| P/S LTM | x | 1.02 | 1.03 | ||||||
| P/FCF LTM | x | 6.12 | 5.26 | ||||||
| EV/EBITDA LTM | x | 39.51 | 74.96 | ||||||
| EV/Sales LTM | x | 1.37 | 1.38 | ||||||
| Earnings Yield LTM | % | -7.56% | -7.15% | ||||||
| FCF Yield | % | +16.34% | +19.02% | ||||||
| Quality | |||||||||
| ROE | % | +13.06% | +14.18% | ||||||
| ROIC | % | +10.79% | -0.22% | ||||||
| Operating margin | % | +15.34% | -0.33% | ||||||
| Gross margin | % | +76.63% | +77.34% | ||||||
| FCF/Sales | % | +16.63% | +19.63% | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | - | - | ||||||
| Sales Growth YoY | % | -1.31% | -2.68% | ||||||
| Net Income Growth YoY | % | - | - | ||||||
| FCF Growth | % | +118.02% | +153.80% | ||||||
| Operating Profit Growth | % | +39.10% | - | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | +10.06% | 0.00% | ||||||
| Dividend Growth | % | -38.39% | -100.00% | ||||||
| Payout Ratio | % | -133.49% | 0.00% | ||||||
| FCF/Debt | x | 0.45 | 0.68 | ||||||
| Net Debt/EBITDA | x | 10.24 | 14.61 | ||||||
| EBIT/Net interest | x | 2.34 | -0.05 | ||||||
| Net debt/market cap | % | +33.18% | +25.21% | ||||||
| Net debt/Equity | x | -0.40 | -0.29 | ||||||
| Gross debt/equity | x | -0.62 | -0.50 | ||||||
Price target estimates
Based on consensus from external analysts. Not Kvantra's opinion.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
ESG
| Metric | 2024 | 2025 | 2026 |
|---|---|---|---|
| ESG-score | |||
| Environmental score | |||
| Social score | |||
| Governance score | |||
| Risk rating |
Company overview
Cryo-Cell International, Inc. engages in cord blood and cord tissue cryopreservation services in the United States. The company offers cellular processing and cryogenic storage for family use, primarily for collection and preservation of umbilical cord blood, and tissue stem cells; and cellular processing and cryogenic storage of umbilical cord blood stem cells for public use. It is also involved in the manufacturing of PrepaCyte CB processing system units for processing umbilical cord blood stem cells. In addition, the company provides cold storage services to third-party pharmaceutical companies and medical institutions. It markets its cord blood stem cell preservation services directly to expectant parents, as well as by distributing information through obstetricians, pediatricians, childbirth educators, certified nurse-midwives, and other related healthcare professionals. The company was incorporated in 1989 and is headquartered in Oldsmar, Florida.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Cryo-Cell International, Inc. (CCEL)
No price history available.
Consensus from external analysts. Not Kvantra's opinion.
Based on consensus from external analysts. Not Kvantra's opinion.
Cryo-Cell International, Inc. engages in cord blood and cord tissue cryopreservation services in the United States. The company offers cellular processing and cryogenic storage for family use, primarily for collection and preservation of umbilical cord blood, and tissue stem cells; and cellular processing and cryogenic storage of umbilical cord blood stem cells for public use. It is also involved in the manufacturing of PrepaCyte CB processing system units for processing umbilical cord blood stem cells. In addition, the company provides cold storage services to third-party pharmaceutical companies and medical institutions. It markets its cord blood stem cell preservation services directly to expectant parents, as well as by distributing information through obstetricians, pediatricians, childbirth educators, certified nurse-midwives, and other related healthcare professionals. The company was incorporated in 1989 and is headquartered in Oldsmar, Florida.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free